| Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene |
2016-12-01 |
| Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II |
2016-12-01 |
| Roche–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech |
2016-12-01 |
| Valneva–France (govt): investment, 201612 existent Bpifrance is 2nd largest shareholder owning 9.6% |
2016-12-01 |
| Valneva–Grimaud: investment, 201612 existent Groupe Grimaud is largest shareholder owning 15.6% |
2016-12-01 |
| Valneva–MVM: investment, 201612 private placement €7.5m w 2.9m new shares at €2.6 to MVM plus acqu existing shares results in 7.5% MVM share |
2016-12-01 |
| Boehringer–ACD/Labs: cheminformatics, 201611– supply deployment of ACD/Spectrus platform by Boehringer in Europe + North America |
2016-11-30 |
| Evotec–Merck (DE): target discovery technology, 201611– collab agreements to combine Merck genome editing technologies w Evotec screening (LT) |
2016-11-30 |
| G7 Therapeutics–Sosei: investment, 201611– acquisition 100% for CHF12m in cash of G7 Therapeutics by Heptares |
2016-11-30 |
| Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy |
2016-11-30 |
| AudioCure Pharma–High-Tech Gründerfonds: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors |
2016-11-29 |
| AudioCure Pharma–MED-EL: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors |
2016-11-29 |
| AudioCure Pharma–SEVERAL: investment, 201611 financing round €9m from new investor MED-EL + existing investor HTGF + private investors |
2016-11-29 |
| GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services |
2016-11-29 |
| Jackson Laboratory–Agilent: grant, 201611– Thought Leader Award to Peter Robinson at Jackons Lab for Genomic Medicine for clinical genomics research |
2016-11-28 |
| Menarini–Chugai: cancer drug, 201611– license ww excl for class I PI3K inhibitor PA799 to Berlin-Chemie Menarini |
2016-11-28 |
| Themis Bioscience–SEVERAL: investment, 201611 financing round Series B €10m 2nd + final closing with additional €3m |
2016-11-28 |
| T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors |
2016-11-23 |
| Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug |
2016-11-22 |
| Horizon Discovery–Sophia Genetics: genomic cancer testing, 201611– collab €na integrating HDx Reference Standards w DDM Platform for NGS cancer tests |
2016-11-17 |
| Epigenomics–Cathay Fortune: investment, 201611 private placement €2.1m w 474.8k new shares at €4.52/share fully subscribed by Cathay Fortune |
2016-11-16 |
| HTG–Qiagen: investment, 201611 minority investment by Qiagen North American Holdings as part of CDx collaboration |
2016-11-16 |
| Qiagen–HTG: molecular companion diagnostics, 201611– collab developm complete NGS solution from biomarker to CDx test |
2016-11-16 |
| Thar Pharmaceuticals–Grünenthal: investment, 201611 acquisition of Thar by Grünenthal |
2016-11-16 |
| UroMems–SEVERAL: investment, 201611 financing round Series A €12m led by Wellington Partners |
2016-11-16 |
| MorphoSys–BVF Partners: investment, 201611 private placement totalling €115m incl €52.8m from BVF Partners acquiring 1.2m shares at €44/share |
2016-11-15 |
| MorphoSys–SEVERAL: investment, 201611 private placement €115m w 2.622m new shares at €44/share to European + North American institutional investors |
2016-11-15 |
| OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform |
2016-11-15 |
| Roche–SEVERAL: cancer immunotherapy, 201611– establishment of imCORE Network by Roche with 21 ww academic centers |
2016-11-15 |
| Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI |
2016-11-10 |
| Kaye Scholer–Arnold & Porter: investment, 201611–201701 merger into Arnold & Porter Kaye Scholer LLP |
2016-11-10 |
| Qiagen–Genohm: LIMS, –201610– collab developm GeneRead Link middleware to connect GeneReader NGS data with LIMS |
2016-11-09 |
| CureVac–SEVERAL: investment, 201611 financing $29.5m led by new investors LBBW Asset (for BWVÄZT) + Landeskreditbank BW |
2016-11-08 |
| Epigenomics–SEVERAL: investment, 201611 private placement €5m 1.035m new shares at €4.83/share to UChip Technology Ltd + BioChain (BVI) Inc |
2016-11-07 |
| Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution |
2016-11-07 |
| Aimmune Therapeutics–Nestlé: investment, 201611 equity investment $145m w 7.6m shares at $19.2/share by Nestlé Health Science |
2016-11-04 |
| Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science |
2016-11-04 |
| Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion |
2016-11-03 |
| AMP-Therapeutics–EnBiotix: investment, 201611 acquisition of AMPT via asset acquisition by newly established EnBiotix GmbH |
2016-11-03 |
| Merck (DE)–BioMed X: pharma research, 201611– collab Merck expansion funding new cancer research groups at BioMed X |
2016-11-03 |
| NBE Therapeutics–Boehringer: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors |
2016-11-03 |
| NBE Therapeutics–SEVERAL: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors |
2016-11-03 |
| Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies |
2016-11-03 |
| Bruker–OTHER: nucleic acid diagnostics, 201611 acquisition €na of NAT assays + PCR techn assets in Glasgow for MALDI Biotyper platform |
2016-11-02 |
| Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology |
2016-11-02 |
| Calibration Technology (IE)–Eppendorf: investment, 201611 acquisition of CTL by Eppendorf |
2016-11-01 |
| Q Laboratories–Bruker: mass spectrometer, 201611 supply MALDI Biotyper |
2016-11-01 |
| Sotax–Waters: liquid chromatography, 201611– distribution rights for Acquity UPLC H-Class Sytem for pharma labs in several countries for Sotax |
2016-11-01 |
| Ganymed–Astellas: investment, 201610– acquisition 100% of Ganymed for €422m upfront + €860m milestones by Astellas Pharma Inc |
2016-10-28 |
| Ganymed–Freshfields: legal services, 201610 advisor for Ganymed owners for sale of Ganymed to Astellas |
2016-10-28 |
| Mologen–Freshfields: legal services, 201610 advisor for capital increase + convertible bond issue |
2016-10-28 |
| BoneSupport–SEVERAL: investment, 201610 raised $47m (SEK327m) in combination of equity + debt finance |
2016-10-27 |
| Evolva–ERS Genomics: CRISPR technology, 201610– license ww non-excl €na to CRISPR technology for industrial applications |
2016-10-27 |
| Inositec–Halsin Partners: public relations, 201610 service existent by Halsin Partners |
2016-10-27 |
| Inositec–SEVERAL: investment, 201610 seed financing round CHF1.4m ($1.42m) from VI Partners via Venture Incubator Fund + Zürcher Kantonalbank |
2016-10-27 |
| Cyprotex–Evotec: investment, 201610–201612 acquisition £55.7m=€66.3m in cash for all 26.1m shares + funding of all debt |
2016-10-26 |
| Nordic Nanovector–Wilex: antibody-drug conjugates, 201610– collab developm of ADCs for leukemias with Heidelberg Pharma |
2016-10-26 |
| NBE Therapeutics–PPF Group: investment, 201610–201611 PPF commits to invest CHF10m in next financing round of NBE as part of collab w Sotio as |
2016-10-20 |
| PPF Group–NBE Therapeutics: antibody-drug conjugates, 201610– collab + license agreem of NBE + Sotio as |
2016-10-20 |
| Schwabe Pharmaceuticals–ACD/Labs: cheminformatics, 201610– supply deployment of ACD/Spectrus platform by Willmar Schwabe Pharmaceuticals |
2016-10-19 |
| ADC Therapeutics–SEVERAL: investment, 201610 private financing round $105m incl Auven Therapeutics + Wild Family Office + AstraZeneca |
2016-10-18 |
| Science 37–Novartis: investment, 201610 financing round Series B totalling $31m incl existing + co-investor dRx Capital |
2016-10-18 |
| Science 37–SEVERAL: investment, 201610 financing round Series B $31m led by Redmile Group + incl Lux Capital + dRx Capital + SGBV |
2016-10-18 |
| Hookipa–Austria (govt): grant, 201610 5th FFG grant €4.16m to develop arenavirus vector-based cancer immunotherapies |
2016-10-17 |
| ObsEva–SEVERAL: investment, 201610–201701 IPO $96.75m+$14.513m w 645k+967.5k common shares at $15/share at Nasdaq Global Select Market |
2016-10-17 |
| Max Planck–Labfolder: electronic lab notebook, 201610– supply license for up to 11k MPI researchers using Labfolder s/w |
2016-10-12 |
| UgiSense–SEVERAL: investment, 201610 first financing round €1.2m from private investors |
2016-10-12 |
| Merck (DE)–HTG: molecular companion diagnostics, 201610– collab master CDx agreement with HTG Molecular Diagnostics |
2016-10-11 |
| Helsinn–Consilium: public relations, 201610 service existent by CSC |
2016-10-10 |
| Mei Pharma–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA |
2016-10-10 |
| OncoResponse–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA |
2016-10-10 |
| QuantuMDx–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA |
2016-10-10 |
| Selexis–Sam Brown: public relations, 201610 service existent by Sam Brown Inc |
2016-10-10 |
| Newron–SEVERAL: investment, 201610 capital increase CHF26.1m private placement 1.32m new shares at CHF19.75/share |
2016-10-06 |
| Kibion–Mayoly Spindler: investment, 201610 acquisition of Kibion AB by Mayoly Spindler |
2016-10-05 |
| Probiodrug–SEVERAL: investment, 201610 capital increase €14.9m w 744k new shares at €20/share representing 10% of issued share capital |
2016-10-05 |
| Carrick Therapeutics–Evotec: drug discovery services, 201610– collab strategic alliance discovery + preclinical services for novel oncology targets |
2016-10-04 |
| Carrick Therapeutics–Evotec: investment, 201610 1st financing round totalling $95m incl up to $6m from co-investor Evotec AG |
2016-10-03 |
| Carrick Therapeutics–SEVERAL: investment, 201610 1st financing round $95m co-led by ARCH Venture Partners + Woodford Investment |
2016-10-03 |
| Bellevue–SEVERAL: investment, 201610–201612 initial offering £150m + listing at LSE of BB Healthcare Trust plc managed by Bellevue Asset Management AG |
2016-10-01 |
| Depomed–Grünenthal: pain drug, 201609 collab existent cebranopadol developm + marketing rights for US for Depomed |
2016-09-30 |
| EngMab–Celgene: investment, 201609 acquisition of EngMab AG for $600m |
2016-09-30 |
| Noxxon–OTHER: investment, 201609 listing of ordinary shares on Alternext Paris [no new shares issued] |
2016-09-30 |
| Noxxon–SEVERAL: investment, 201609 private placement just prior to listing of ordinary shares on Alternext Paris |
2016-09-30 |
| Bluebird Bio–Medigene: TCR technology, 201609– collab strategic alliance $15m upfront + up to over $1b funding/milestones + royalties |
2016-09-29 |
| Boehringer–Hospital Corp of America: clinical research, 201609– collab clinical developm of combi of 2 checkpoint inhibitors w Sarah Cannon Research |
2016-09-29 |
| ICMP–Qiagen: MDx forensics, 201609– collab developm NGS workflow for identification of missing persons |
2016-09-29 |
| Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products |
2016-09-28 |
| Immunic–4SC: immune modulatory compounds, 201609 acquisition of small molecule immunology portfolio of 4SC by Immunic |
2016-09-28 |
| Noxxon–NewCap: public relations, 201609 service existent by NewCap |
2016-09-28 |
| Immunic–Bavaria (govt): investment, 201609 financing round Series A totalling €17.5m incl co-investor Bayern Kapital |
2016-09-27 |
| Immunic–High-Tech Gründerfonds: investment, 201609 financing round Series A totalling €17.5m incl co-investor HTGF |
2016-09-27 |
| Immunic–Life Sciences Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners |
2016-09-27 |
| Immunic–LifeCare Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners |
2016-09-27 |
| Immunic–SEVERAL: investment, 201609 financing round Series A €17.5m co-led by LSP + LifeCare Partners |
2016-09-27 |
| NeuRoWeg project–Grünenthal: companion diagnostics, 201609– Grünenthal is partner in project for efficacy tests for neuropathic pain drugs |
2016-09-27 |
| NeuRoWeg project–Life & Brain: companion diagnostics, 201609– Life & Brain GmbH is partner in project for efficacy tests for neuropathic pain drugs |
2016-09-27 |
| NeuRoWeg project–North Rhine-Westphalia (govt): grant, 201609– EFRD/NRW €1.5m grant to develop test for efficacy of neuropathic pain drugs |
2016-09-27 |
| NeuRoWeg project–Univ Bonn: companion diagnostics, 201609– Univ Hospital Bonn is partner in project for efficacy tests for neuropathic pain drugs |
2016-09-27 |
| NeuRoWeg project–Univ Cologne: companion diagnostics, 201609– Univ Hospital Cologne partner in project for efficacy tests for neuropathic pain drugs |
2016-09-27 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 25 26 27 ... 29 30 31 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
